Aida Pharmaceuticals (AIDA)

[PaperProphet]

From the 10KSB, it looks like they had enough cash to pay for the Nanwang fiasco. The 8-K also says it was "paid." I don't know what the terms are but it's possible they also may have to find another guarantor for their loans now that Nanwang is out of the picture.

It's too bad that they needed guarantors. It looks like they're doing very well on their own. Hopefully they'll be able to recover a good portion of what they paid from Nanwang's assets.

It's rare to find a company this size which is actually producing income while they're producing new drugs. I looked through a number of companies before I found Aida and it impressed me. However, I'm probably not going to put any more money into it until it stabalizes or I'm more comfortable. I suppose I'll have to see what the future brings.

Two big pieces of news coming out. The first is the earnings. Third quarter was $0.02. Fourth quarter was $0.08. Hopefully they'll keep on going--although I don't have enough information on that other than extrapolating out. I know China mandated that drugs could no longer be purchased through distributors which forced Aida to change their sales. The reasoning apparently was to stop counterfeiting which since counterfeit drugs generally enter through distributors. Sales may cost a bit more but that policy should ultimately benefit Aida.

The second piece of news is the phase II results of Rh-Apo2L. Those statistical results will be much more likely to make the market. Otherwise, it's hard to put numbers on opinions. As nice as "extremely positive" sounds, it's not quantifiable.